Glenview Capital Management’s Ginkgo Bioworks DNA Stock Holding History

Glenview Capital Management’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-149,379	Closed	-$1.24M	–	50
2025 Q4	$1.24M	Hold	149,379	–	–	0.03%	56
2025 Q3	$2.18M	Hold	149,379	–	–	0.05%	53
2025 Q2	$1.68M	Sell	149,379 -38,122	-20%	-$295K	0.05%	41
2025 Q1	$1.07M	Hold	187,501	–	–	0.03%	44
2024 Q4	$1.84M	Sell	187,501 -287,497	-61%	-$2.46M	0.05%	34
2024 Q3	$3.87M	Sell	474,998 -187,502	-28%	-$1.88M	0.07%	41
2024 Q2	$8.86M	Buy	662,500 +62,500	+10%	+$1.86M	0.17%	43
2024 Q1	$27.8M	Buy	+600,000	New	+$31.1M	0.49%	32

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Glenview Capital Management's DNA Position: Q1 2026 in Review

Glenview Capital Management sold out of Ginkgo Bioworks (DNA) in Q1 2026, closing a stake of 149,379 shares — an estimated $1.24M sold.

Glenview Capital Management first reported a position in DNA in Q1 2024 and held it in 8 quarters. The position peaked at $27.8M in Q1 2024. 175 funds tracked by Wall St. Rank hold DNA as of Q1 2026.

Glenview Capital Management reported no remaining Ginkgo Bioworks position as of Q1 2026 after selling out during the quarter.
Glenview Capital Management sold 149,379 Ginkgo Bioworks shares in Q1 2026, an estimated $1.24M.
Glenview Capital Management first reported a position in Ginkgo Bioworks in Q1 2024 and held it in 8 quarters.
Glenview Capital Management's Ginkgo Bioworks position peaked at $27.8M in Q1 2024.
175 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2026.

Based on Glenview Capital Management's 13F filing for Q1 2026, filed 15 May 2026.